Orphazyme Investor Relations Material
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company's lead drug candidate is epoprostenol sodium and its analogues, Phase III ready lipidic compounds, which are being developed as an innovative treatment option targeting the underlying cause of these diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark
Upcoming events for
(EST) FY 20222023-04-28
H1 20222022-09-20
Latest company events
Ticker symbol
ORPHA
Country
Denmark
About the company
Investor Relations Page
Dig deeper into the Orphazyme fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
